• Users Online: 14087
  • Print this page
  • Email this page
Year : 2021  |  Volume : 4  |  Issue : 3  |  Page : 516-523

Biomarker series: KRAS- A narrative review

1 Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India
2 Department of Section of Molecular Diagnostics, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India

Correspondence Address:
Ullas Batra
Sector 5, Rohini, Sir Chhotu Ram Marg, New Delhi - 110 085
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/crst.crst_189_21

Get Permissions

Non-small cell lung cancer (NSCLC) has emerged as the poster child of molecular medicine. Kirsten rat sarcoma (KRAS)-mutated NSCLC is a common yet heterogeneous entity with distinct clinical and prognostic characteristics. Therapeutically, targeting the KRAS mutation in NSCLC has been the most difficult challenge faced by scientists and drug developers and after decades of efforts, a final breakthrough in the form of KRAS G12C inhibitors has emerged. In this edition of the biomarker series, we review KRAS, its biology, clinical features, and the therapeutic options in KRAS-mutant NSCLC. We performed a thorough search in PubMed, Embase, and Scopus and finally included 59 articles to write this review.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded47    
    Comments [Add]    

Recommend this journal